Federal Circuit Reverses and Remands in RegenxBio v. Sarepta AAV Patent Dispute
Navigating Gene Therapy IP?
Choose your path based on your current needs in the AAV patent landscape:
📋 Case Summary
| Case Name | RegenxBio, Inc. v. Sarepta Therapeutics, Inc. |
| Case Number | 24-1408 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District Court |
| Duration | Jan 2024 – Feb 2026 751 days |
| Outcome | Reversed & Remanded |
| Patents at Issue | |
| Accused Products/Method | Sarepta’s use of AAV sequence detection and isolation methods |
Case Overview
The Parties
⚖️ Plaintiff
Clinical-stage biotechnology company with extensive AAV gene delivery technology IP. Licenses its NAV Technology Platform.
🛡️ Defendant
Biopharmaceutical company focused on RNA-targeted therapeutics and gene therapy for rare neuromuscular diseases.
Patents at Issue
This landmark case involved U.S. Patent No. US10526617B2, a foundational patent covering methods for detecting, identifying, and isolating novel adeno-associated virus (AAV) sequences — critical intellectual property in the rapidly expanding gene therapy space.
- • US10526617B2 — Methods for detecting and isolating AAV sequences
Developing AAV-based therapeutics?
Check if your gene therapy platform or method might infringe this or related AAV patents.
The Verdict & Legal Analysis
Outcome
The Federal Circuit ordered the case **REVERSED AND REMANDED**, vacating the lower court’s decision and returning the matter for proceedings consistent with the appellate court’s findings. No specific damages amount or final injunctive relief determination was reported at the appellate stage given the remand posture.
Key Legal Issues
The Federal Circuit’s reversal signals that the lower court’s analysis required material correction, likely stemming from a **claim construction error** or improper application of infringement/validity standards. This highlights the critical role of method claim interpretation for AAV sequence detection and isolation in gene therapy research and manufacturing contexts.
Drafting an AAV method patent?
Learn from this case. Use AI to draft stronger method claims that can withstand litigation.
Power Your Patent Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in AAV gene therapy. Choose your next step:
📋 Understand This Case’s AAV Impact
Learn about the specific risks and implications for AAV sequence detection and isolation.
- View all related AAV patents and vectors
- See which companies are most active in gene therapy IP
- Understand method claim construction in biologics
🔍 Check My AAV Product’s Risk
Run a comprehensive FTO analysis for your own AAV-based technology or product.
- Input your AAV platform description or technical features
- AI identifies potentially blocking AAV method patents
- Get actionable risk assessment report for gene therapies
High Risk Area
AAV sequence detection & isolation methods
US10526617B2
Core AAV method patent
Design-Around Options
Explore alternative AAV methodologies
✅ Key Takeaways
For Gene Therapy Patent Attorneys
Federal Circuit claim construction for method claims in biotechnology can be critical for infringement outcomes.
Search related AAV cases →Appellate review is a high-value strategic tool for foundational platform IP in gene therapy.
Explore Federal Circuit precedents →For AAV R&D Teams
Thoroughly document AAV sequence detection and isolation methods and conduct FTO analysis before advancing programs.
Start FTO analysis for my AAV product →Proactively conduct IP clearance reviews for AAV-based programs and consider early patent filings.
Try AI patent drafting for gene therapy →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.